Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies

Table 2

Influence of autoantibodies against tumor-associated antigens on the prognosis of cancer patients.

Autoantibody specificity	Number of patients	Tumor type	Impact	Ref.
Laminin	71	Breast cancer	Decreased OS	[44]
HSP90	327	Breast cancer	Decreased OS	[45]
p53	9489	Breast, gastric, colon cancer, NSCLC and oral cancer	Decreased OS	[46]
NY-ESO-1	207	Prostate cancer	Decreased OS	[47]
Nucleophosmin	100	Breast cancer	Decreased RFS	[48]
Panel of 29 antigens	60/59	Ovarian cancer/pancreatic cancer	Increased OS	[49]
CTSP-1	147	Prostate cancer	Increased RFS	[50]
p53	130	HCC	Increased RFS	[51]
Laminin-Receptor	67	CLL	Increased RFS	[52]
CML66	15	CML	Increased RFS	[53]
GLEA3 and PHF3	62	Glioblastoma	Increased OS	[54]
MUC1	30	NSCLC	Increased RFS	[18]
MUC1	100	Ovarian cancer	Increased OS	[55]
MUC5AC	30	Colon cancer	Increased OS	[56]
SOX1	90	SCLC	Increased OS	[57]
CEA	52	Breast cancer	Increased RFS	[58]
SEREX clones	12	Meningioma	None	[59]
SCP1	100	Pancreatic cancer	None	[60]
Cyclin B1	42	AML	None	[61]
p53	120	Oral cancer	None	[6]
Hsp90	116	Ovarian cancer	None	[62]
ALK	21	ALL	None	[63]
SEREX clones	25	SCC	None	[64]
MUC-1	125	Breast cancer	None	[65]
Survivin	76	NSCLC	None	[66]
NY-ESO-1	12	Different cancers	None	[67]
NY-ESO-1	69	Esophageal cancer	None	[68]
Phage Display clones	176	Breast cancer	None	[69]
Braf	372	Melanoma	None	[70]

OS: overall survival, RFS: recurrence-free survival.